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Abstract The p16INK4a tumor suppressor negatively regulates
progression through the G1 phase of the mammalian cell cycle.
To mimic the downmodulation of p16INK4a commonly seen in
cancer, we designed and characterized a hammerhead ribozyme
against exon E1K of the murine p16INK4a transcript. Stable
expression of the ribozyme in murine erythroleukemia (MEL)
cells reduced the endogenous p16INK4a protein by more than 70%
and significantly accelerated cell cycle progression. The speci-
ficity and efficiency of our new ribozyme suggest its possible
application in elucidating the role of p16INK4a in fundamental
biological processes including homeostatic tissue renewal,
protection against oncogenic transformation, and cellular
senescence.
z 1998 Federation of European Biochemical Societies.
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1. Introduction
Progression through the mammalian cell division cycle is
controlled by periodic activation of the cyclin-dependent kin-
ases (Cdks) [1,2]. The Cdks are activated by association with
their regulatory partners, the cyclins, whose expression oscil-
lates throughout the cell division cycle [1]. In mid-to-late G1
phase of the cell cycle Cdk4 and Cdk6 assemble with D-type
cyclins and phosphorylate their major substrate, the retino-
blastoma protein (pRb) [2,3]. In its hypophosphorylated state,
pRb binds diverse transcription factors including E2F and
acts as a negative cell cycle regulator by preventing S-phase
entry. The phosphorylation of pRb in late G1 releases E2F
which in turn triggers expression of genes essential for S-phase
entry and progression through the cell cycle [3,4].
The p16INK4a tumor suppressor protein negatively regulates
the progression of cells through the G1 phase of the cell cycle
by inhibiting the functions of Cdk4 and Cdk6 [5,6]. Loss of
functional p16INK4a results in upregulated Cdk4/Cdk6 kinase
activity, leading to persistent pRb hyperphosphorylation and
thereby contributes to deregulation of cellular proliferation.
The involvement of p16INK4a in carcinogenesis was established
by observations that the INK4a locus is mutated, deleted, or
silenced by promoter methylation in a number of human can-
cer types [2,7,8].
The INK4a locus has the unusual capacity to generate two
transcripts derived from di¡erent promoters. Each transcript
has a unique 5P exon, E1K and E1L, each of which is joined to
exon 2 and 3 through a common splice acceptor site in exon 2.
The K and L transcripts encode two di¡erent proteins. The
K transcript encodes p16INK4a, whereas the L transcript
encodes the p19ARF protein from an alternative reading frame
initiated within the E1L exon [9^11].
Here we have designed ribozymes targeted to the p16INK4a K
transcript in order to provide a speci¢c tool to downmodulate
the expression of p16INK4a as an approach to study its func-
tion. The potential of using trans-acting ribozymes to study
the function of a particular gene is underscored by their at-
tractive features as catalysts: they have the capacity of cleav-
ing RNA, and potentially inactivate multiple copies of a tar-
get RNA [12]. Furthermore, ribozymes might be more
e¡ective than antisense strands even under non-turnover con-
ditions because their activity cleaves the target, thereby elim-
inating the possibility that subsequent denaturation of the
complex could reactivate the target RNA [13].
Despite recent progress, the development of e¡ective ribo-
zymes for in vivo applications is still di⁄cult and strongly
depends on the rational design of the ribozyme. There are
several aspects important for the successful application, in-
cluding ribozyme kinetics, its stability, target site accessibility,
expression strategy and ribozyme-target colocalization [14,15].
The utilization of ribozyme expression cassettes as carriers
for ribozymes was shown to ful¢l several criteria for in vivo
applications. Expression units based on naturally occurring
RNAs like tRNA [16] or Va I RNA derived from adenovirus
[14,17,18] allow for high-level polymerase III expression and a
stable structure of the ribozyme. These expression strategies
furthermore deliver the ribozyme to the cytoplasm and should
colocalize it with the target RNA [19].
In this paper, we have used an optimized ribozyme expres-
sion cassette based on the Va I gene derived from adenovirus
type 2 [14]. We show that the ribozyme embedded in the
expression cassette can cleave both in vitro and in vivo and
is able to downmodulate the p16INK4a protein level by at least
70% when expressed in mouse erythroleukemia (MEL) cells.
Furthermore, MEL clones expressing the ribozyme construct
gained a signi¢cant proliferative advantage.
2. Materials and methods
2.1. Plasmid constructs
The murine p16INK4a full-length cDNA construct was made by
combining two cDNA clones: one containing the untranslated 5P
region and coding region (kindly provided by Manuel Serrano,
Cold Spring Harbor) and another clone with the coding sequence
and the 3P untranslated region (kindly given by Dawn Quelle, St.
Jude Research Hospital). The 5P clone was PCR ampli¢ed and sub-
cloned into the pCRII (Invitrogen) vector and the 3P clone was in-
serted into the KpnI/Bsp1191 sites generating the full-length mouse
cDNA clone pCRII-p16INK4a.
The ribozyme constructs were made by fusing oligonucleotides
(DNA Technology) representing each strand. The ribozyme sequences
containing XhoI/NsiI sites were cloned into the SalI/PstI sites in the
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Gval plasmid as according to [14]. The sequences of the ribozyme
oligonucleotides were: Rz 89-12: 5P-CGAGCAGCGCTGATGAGT-
CCGTGAGGACGAAACTCCAATGCA-3P and 5P-TTGGAGTTT-




The Va expression cassette containing Rz 89-12 was excised using
XbaI and HindIII and cloned into the SpeI-HindIII sites in the cyto-
megalovirus (CMV) promoter plasmid, pX [20].
2.2. In vitro transcription
In vitro transcription was performed by incubating 2 Wg of linear-
ized template (HindIII linearized pCRII-p16INK4a or NheI linearized
Gval vector) in RNA polymerase bu¡er with 25 units of T7 RNA
polymerase (Biolabs) for 1 h at 37‡C according to manufacturers
speci¢cations. In the p16INK4a transcription reaction, 2 mM GTP,
ATP, UTP and 1 mM CTP plus 5 WCi of [32P]-CTP was included.
2.3. Ribozyme cleavage in vitro
In vitro cleavage was done by incubating di¡erent molar ratios of
labeled p16INK4a RNA and ribozyme RNA in 50 mM Tris-HCl (pH
7.5). The reactions were incubated at 95‡C for 90 s and subsequently
cooled on ice. MgCl2 was added (or excluded) to a ¢nal concentration
of 10 mM and the 20 Wl reactions were incubated at 37‡C for 1 h. Ten
Wl of stop bu¡er (95% formamide, 20 mM EDTA, 0.05% bromphenol
blue, 0.05% xylene cyanol) was added and the reactions were loaded
on a 5% denaturing polyacrylamide gel and run in Tris-Borate bu¡er.
The gels were exposed on a phosphorimager screen.
2.4. TNT coupled transcription/translation assay
130 ng of HindIII linearized pCRII-p16INK4a or pCMV human
p16INK4a plasmid was incubated with 1 Wg or 2 Wg of HindIII linear-
ized plasmids of ribozymes or Gval vector (plasmid ratio 1:5 or 1:10).
The plasmid DNA was mixed with TNT rabbit reticulocyte lysate
(Promega), reaction bu¡er, amino acid mix (-met), 35S-methionine,
RNasin and T7 RNA polymerase and incubated at 30‡C for 1.5 h
according to manufacturers instructions. 1/5 of each reaction mixture
were analyzed by 15% SDS-PAGE.
2.5. Tissue culture and transfections
MEL cells, DS19/Sc9 derived from 745A cells [21] were maintained
in K-minimal essential medium (Sigma) supplemented with 10% fetal
calf serum (Gibco Brl) at 37‡C in a humidi¢ed 5% CO2 atmosphere.
Establishment of stable transfected clones was performed by the pX-
ribozyme construct with a neomycin gene containing plasmid (pCMV-
Neo) in the molar ratio of 10:1 using electroporation (settings: 300 V;
250 WFD; r 6). Cells were cultured in medium supplemented with
1 mg/ml G-418 sulphate (Life Technologies) and resistant clones were
isolated after 12 days. Clones were screened for ribozyme expression
by RT-PCR using primers speci¢c for the Va I-Va II genes.
2.6. Northern blotting
Total RNA from MEL cells was puri¢ed using the guanidinium
thiocyanate method as described [22]. Ten Wg of total RNA from
each clone was separated on denaturing formaldehyde gel and blotted
onto Hybond-N nylon membrane (Amersham) using capillary trans-
fer. The probes were generated using the random primed labeling kit
(Boehringer Mannheim) by incorporation of [K32P]-dCTP. A full-
length p16INK4a DNA fragment was labeled and used as the probe.
The blots were exposed on a phosphorimager screen.
2.7. Immunoblotting
Cells were harvested, frozen in liquid nitrogen and proteins ex-
tracted in bu¡er containing 50 mM HEPES (pH 7.5), 250 mM
NaCl, 5 mM EDTA, 0.1% NP-40, 1 mM DTT (Protease inhibitors:
leupeptin 2.5 Wg/ml, aprotinin 2 Wg/ml, PMSF 50 Wg/ml). Western
blotting was performed according to standard procedures using Bio-
Rad minigel apparatus, semidry blotting equipment (Millipore) and
nitrocellulose membranes (MFS). Protein bands were visualized by
enhanced chemiluminescence (Amersham). For detection of p16INK4a
protein, a rabbit polyclonal antibody against mouse p16INK4a was used
(Santa Cruz Biotechnology). Cdk4 protein was detected by an anti-
body (DCS 31) recognizing an epitope corresponding to amino acids
15^25 of Cdk4 (our unpublished results).
3. Results
3.1. Cleavage of mp16INK4a mRNA in vitro by a transcribed
ribozyme
Accessible ribozyme cleavage sites within mouse p16INK4a
RNA were chosen on the basis of a computer assisted pre-
diction of the RNA secondary structure (RNAFOLD pro-
gram, Wisconsin package). Only those potential cleavage sites
predicted to be in single-stranded loop structures were consid-
ered. The GUC site at nucleotide (nt) 89 positioned just after
the start codon in exon E1K [23] was chosen and ribozyme
genes were designed against this cleavage site. The length of
the complementary ribozyme recognition sequences (helices I
and III) were either 15 nt (Rz 89-15) or 12 nt (Rz 89-12) (Fig.
1A). The shorter £anking nt in Rz 89-12 might facilitate a
faster dissociation of the ribozyme from the cleaved substrate
and allow further ribozyme turnover reactions to occur.
In order to obtain ribozymes for in vivo applications, the
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Fig. 1. Properties of the ribozyme (A) nucleotide sequence of Rz
89-12. The cleavage site at nt 89 in the p16INK4a transcript is indi-
cated (arrow). B: In vitro cleavage analysis of the ribozyme Va ex-
pression unit. Ribozyme RNA and labeled p16INK4a RNA substrate
were combined in 10 mM MgCl2, heat denatured and incubated at
37‡C for 1 h. The samples were run on a 5% denaturing polyacryl-
amide gel with a [32P]-labeled DNA marker. Lanes 1^3: Rz 89-12
and p16INK4a in the molar ratios 10:1, 20:1 and 50:1. Lanes 4^5:
Va RNA (minus ribozyme) and p16INK4a in the ratios 20:1 and
50:1 (negative control). Lane 6: Rz 89-12 and p16INK4a in the ratio
50:1 without MgCl2. The full-length p16INK4a transcript (912 nt)
and the 155 nt cleavage fragment are indicated by arrows.
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ribozymes were cloned into an adenovirus Va RNA expres-
sion cassette. The cassette contains a chimerical stem-loop
sequence allowing the catalytic sequences to be formed inde-
pendently from surrounding RNA structures [14]. To asses the
ability of the designed ribozymes embedded in Va expression
cassettes to cleave in vitro, RNAs were synthesized and incu-
bated with radiolabeled substrate RNA. The 912 nucleotide
substrate RNA (846 nucleotides of p16INK4a plus 66 nt of
vector sequence) was prepared by in vitro transcription. In
each reaction, 100 nM of labeled p16INK4a RNA were incu-
bated with ribozyme RNA in di¡erent molar ratios (Fig. 1B).
Similar cleavage activities were observed for Rz 89-15 (not
shown) and Rz 89-12 and cleavage generated the expected
small 5P fragment of 155 nucleotides (89 nucleotides of
p16INK4a plus 66 nt derived from the vector sequence). The
larger cleavage fragment (757 nt) generated was not recogniz-
able because of dominant heterogeneous transcripts arisen
during the in vitro transcription of p16INK4a cDNA. No cleav-
age was detected in the absence of MgCl2 due to the require-
ment for divalent metal ions in cleavage catalysis (Fig. 1B,
lane 6).
3.2. Inhibition of in vitro translation by ribozymes speci¢c
for murine p16INK4a
To further analyze and con¢rm the ribozyme speci¢city for
p16INK4a in vitro, a coupled TNT transcription/translation
system (Promega) was used. The standard assay was used to
detect the ability of the ribozymes to downmodulate p16INK4a
measured on the protein level. 130 ng of substrate p16INK4a
plasmid (pCRII-p16INK4a) was combined with ribozyme plas-
mids or with Gval plasmid (Va cassette minus ribozyme) in
di¡erent molar ratios and incubated at 30‡C for 1.5 h (Fig. 2).
Rz 89-15 and Rz 89-12 reduced the level of p16INK4a consid-
erably. At a molar ratio of 10:1 (ribozyme:substrate), the
level of p16INK4a was reduced by more than 95% (Fig. 2A,
lanes 5 and 6). Both ribozymes seemed to reduce the p16INK4a
level with similar e⁄ciency. To examen whether the ribozyme
activity observed was speci¢c for murine p16INK4a, the ribo-
zymes were incubated with human p16INK4a. No inhibition
was detected in this case (Fig. 2B).
3.3. Function of the stably expressed ribozyme in vivo
In order to study the cleavage e⁄ciency of the ribozyme on
p16INK4a mRNA in vivo, Rz 89-12 was subcloned into a mam-
malian expression vector containing the CMV promoter and a
polyadenylation signal. A murine erythroleukemia cell line
(MEL), known to express a functional pRb [21] and elevated
p16INK4a [23] was chosen as a cellular test system to analyze
the in vivo function of Rz 89-12. Stably transfected clones
were established and two ribozyme expressing clones were
identi¢ed by RT-PCR and further analyzed on the RNA level
by Northern blotting (Fig. 3A). As expected, the level of
p16INK4a mRNA was not reduced in the ribozyme expressing
clones. However, a fraction of the RNA migrates faster and
most likely represents the 757 nt cleavage product generated
by cleaving of 89 nt (Fig. 3A, lanes 3^4). The protein level of
p16INK4a was determined for the di¡erent clones by immuno-
blotting. The two clones expressing Rz 89-12 had signi¢cantly
reduced p16INK4a protein levels (Fig. 3B, lanes 4^5). The re-
duction was estimated to be 73% when compared to the Va
control clones and wild-type cells (Fig. 3B, lanes 1^3). These
results indicate that Rz 89-12 is able to down-regulate the
level of p16INK4a in MEL cells.
3.4. Enhanced proliferation of ribozyme expressing MEL
clones
Growth experiments were performed with ribozyme ex-
pressing clones (clones 3 and 4) derived from the MEL cells
to examine the e¡ect of the p16INK4a reduction on cell prolif-
eration. Exponentially growing MEL clones were seeded in
microtiter plates and allowed to grow. At di¡erent time points
cells were collected and the number of cells counted (Fig. 4).
The two Rz 89-12 clones proliferated considerably faster than
the Va control clones (minus ribozyme) re£ected by shorten-
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Fig. 2. Ribozyme activity assay. In vitro coupled transcription/trans-
lation of p16INK4a plasmid was performed and the 35S methionine
labeled proteins separated by SDS-PAGE on 15% gels. A: Lane 1:
p16INK4a alone. Lanes 2 and 3: Gval vector and p16INK4a in the mo-
lar ratios 5:1 and 10:1 (control). Lanes 4^6: plasmids of Rz 89-15
and Rz 89-12 incubated with p16INK4a in the ratios 5:1, 10:1 and
10:1. B: The two ribozyme plasmids and a human p16INK4a plas-
mid.
Fig. 3. In vivo analysis of ribozyme function. A: Northern blot
analysis of p16INK4a expression of clones stably transfected with the
ribozyme construct. The membrane was probed with a p16INK4a
fragment (900 nt) (upper panel). Lane 1: clone transfected with the
control Va plasmid. Lane 2: wild-type (Wt) cells. Lanes 3^4: two
clones expressing the Rz 89-12 construct. The lower panel shows
glyceraldehyde 3-phosphate dehydrogenase (GAPDH) expression as
control for equal loading. B: Immunoblotting analysis of the
p16INK4a protein (18 kDa) levels (upper panel). Lanes 1^2: two Va
plasmid transfected clones. Lane 3: wild-type cells. Lanes 4^5: the
two clones expressing Rz 89-12. Cdk4 (32 kDa) was used as internal
control for equal loading (lower panel).
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ing of the doubling time to 23 h compared with the 30 h in
control clones. These data suggest that the ribozyme-mediated
reduction in p16INK4a protein levels is associated with accel-
erated progression through the cell cycle.
4. Discussion
The ribozyme technology has recently attracted consider-
able attention as an emerging strategy to selectively inactivate
or downmodulate expression of speci¢c genes, in either tran-
sient or sustained manner, without a¡ecting gene structure.
Despite the wide spectrum of potential biomedical applica-
tions [24], ranging from in vitro studies elucidating the roles
of diverse regulatory proteins, up to gene therapy of human
diseases, the widespread use of the ribozymes has been rather
slow due, at least in part, to technical di⁄culties with their
design (see also Section 1). The successful construction of the
e¡ective p16INK4a-speci¢c ribozyme, reported in our present
study, therefore merits attention from both the point of
view of the technology involved, as well as the potential bio-
logical applications of this new tool.
In terms of the technical aspects, our data support the no-
tion that one of the critical parameters in the design of an
e⁄cient ribozyme is the identi¢cation of accessible single-
stranded cleavage sites within the target RNA [14,15,24].
The choice of cleavage sites exclusively on the basis of se-
quence information often leads to disappointing failures.
Here we have used computer modelling to predict the second-
ary structure of the p16INK4a mRNA, and based on the pre-
dicted minimum energy folding structure, the cleavage site at
nucleotide 89 was chosen as a candidate target. This GUC site
was predicted to be located in an accessible RNA loop struc-
ture according to the obtained computer model, and our re-
sults showed that the p16INK4a-speci¢c ribozymes indeed e⁄-
ciently cleaved the mRNA after nt 89 at the expected site in
vitro. In addition, the ribozymes reduced the level of trans-
lated p16INK4a by more than 95% when examined in the tran-
scription/translation system, though this pronounced e¡ect
likely re£ects the sum of the mRNA cleavage and contribu-
tion of antisense phenomena. Both the Rz 89-15 and Rz 89-12
cleaved with similar e⁄ciency in the in vitro assays, suggesting
that shortening of the target recognition sequence in the latter
ribozyme did not signi¢cantly increase its catalytical activity.
To evaluate the ability of our new ribozyme to inactivate
p16INK4a mRNA in vivo, we generated a series of cell clones
upon stable transfection of the Rz 89-12 construct into murine
erythroleukemia (MEL) cells. This cellular model was chosen
based on the previously shown elevated expression of p16INK4a
[23], and the demonstration that these cells harbor a function-
al RB pathway including the pRB tumor suppressor itself,
and its key upstream regulators cyclin D2, D3, and Cdk4
[21]. The observed expression of the ribozyme in the trans-
fected cells was driven both by the CMV promoter in the
vector sequence, and from the intragenic polymerase III pro-
moter within the Va I gene as determined by Northern blot-
ting (our unpublished data). The signi¢cant e¡ect of the ribo-
zyme in live cells was re£ected by considerably reduced
expression of p16INK4a, resulting in more than 70% decrease
at the protein level. The ribozyme-mediated cleavage after nt
89 did not destabilize the p16INK4a transcript signi¢cantly, as
documented by Northern blotting. On the other hand, the
cleavage generated a truncated transcript which is most likely
not translated to a functional protein in vivo. Evidence for the
cleavage could be found on the RNA blots (see Fig. 3A), in
the form of a shorter, 757-nt cleavage product that migrated
slightly faster compared with the uncleaved product.
As the p16INK4a Cdk inhibitor and tumor suppressor nor-
mally retards or even blocks cell cycle progression [25^27], a
rather strong prediction for a biological e¡ect of an e⁄cient
p16INK4a-speci¢c ribozyme was that the ribozyme expressing
cells may progress through the cell cycle with accelerated
speed. This prediction was con¢rmed by the comparative
growth curve experiments, in that the doubling time of the
clones stably expressing the Rz 89-12 ribozyme was shortened
by approximately 7 h relative to clones transfected with the
vector DNA only. This result is consistent with the current
stoichiometric models of action of the Cdk inhibitors through
their physical interaction and/or disruption of the cyclin-Cdk
complexes [1,5,6]. Since the degree of the biological e¡ects of
Cdk inhibitors including p16INK4a depends on their threshold
level [1,5,6,27] signi¢cant biological e¡ects can be expected
not only following complete elimination, but also under con-
ditions of signi¢cant reduction of the protein. The fact that
the residual 25^30% of the p16INK4a protein are unable to
preserve the normal duration of the cell cycle, leading to the
observed acceleration of proliferation in our model, is remi-
niscent of naturally occurring tumor-associated point muta-
tions of the p16INK4a gene resulting in protein products partly
impaired in their function [27]. In view of the fact that such
partially defective mutations have been selected for during the
course of oncogenesis in vivo, the data presented here suggest
that the expression of our new ribozyme can result in bio-
logically meaningful e¡ects. This conclusion is further sub-
stantiated by the fact that the level of p16INK4a expression in
the majority of cell types, including the primary ¢broblasts or
epithelial cells, is below the level seen in the MEL cell line,
possibly allowing for even more substantial reduction of
p16INK4a levels by our ribozyme if applied in such models.
Finally, the high degree of speci¢city achieved by the ribo-
zyme cleavage, further documented here by its strict selectivity
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Fig. 4. Growth curves of the two Rz 89-12 clones and Va control
clones. Cells were seeded (1.5U105 cells per ml) in duplicates in 24-
well dishes and two wells per clone were harvested and counted at
di¡erent time points. The cell number represents mean values for
each time point. The cell doubling time for each clone was deter-
mined on a logarithmic y-scale (not shown) from 0^75 h. Rz 89-12
clones, T2 = 23 h. Control Va clones, T2 = 30 h. The experiment pre-
sented here is a representative of three independent experiments.
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towards the murine transcript when compared with the hu-
man p16INK4a homologue, suggests its potential application in
the di⁄cult task to distinguish between the e¡ects caused by
the two alternative transcripts encoded by the INK4a locus
[9^11] (see Section 1). The localization of the ribozyme cleav-
age site in exon E1K, and thus outside the sequence that over-
laps with that encoding the p19ARF cell cycle inhibitor [9^11],
indicates that the Rz 89-12 ribozyme could help clarify the
present uncertainty about the role of the mouse p16INK4a as
tumor suppressor. This highly debated issue was raised fol-
lowing demonstration that the tumor-prone phenotype origi-
nally observed in mice homozygously deleted for the exon 2
[28] encoding both the p16INK4a and p19ARF [10] can be largely
recapitulated in gene knock-out animals speci¢cally deprived
of the p19ARF alone [29], thereby leaving the contribution of
p16INK4a to the phenotype, and to mouse oncogenesis in gen-
eral, subject to speculation. This conceptually important issue
however represents only one of numerous potential applica-
tions of speci¢c and e⁄cient ribozymes against p16INK4a, and
it is our hope that this new tool will contribute to elucidation
of the involvement of p16INK4a in regulation of fundamental
biological processes including cell proliferation, replicative
senescence, and multistep tumorigenesis.
Acknowledgements: This work was supported by grants from the
Danish Cancer Society, and the Danish Medical Research Council
(Grant no. 9600821).
References
[1] Pines, J. (1996) Curr. Biol. 6, 1399^1402.
[2] Sherr, C.J. (1996) Science 274, 1672^1677.
[3] Bartek, J., Bartkova, J. and Lukas, J. (1996) Curr. Opin. Cell.
Biol. 8, 805^814.
[4] Weinberg, R.A. (1995) Cell 81, 323^330.
[5] Harper, J.W. and Elledge, S.J. (1996) Curr. Opin. Genet. Dev. 6,
56^64.
[6] Sherr, C.J. and Roberts, J.M. (1995) Genes Dev. 9, 1149^1163.
[7] Hall, M. and Peters, G. (1996) Adv. Cancer Res. 68, 67^108.
[8] Kamb, A. (1995) TIG 11, 136^140.
[9] Stone, S., Jiang, P., Dayananth, P., Tavtigian, S.V., Katcher, H.,
Parry, D., Peters, G. and Kamb, A. (1995) Cancer Res. 55, 2988^
2994.
[10] Quelle, D.E., Zindy, F., Ashmun, R.A. and Sherr, C.J. (1995)
Cell 83, 993^1000.
[11] Duro, D., Bernard, O., Della, V.V., Berger, R. and Larsen, C.J.
(1995) Oncogene 11, 21^29.
[12] Hasselo¡, J. and Gerlach, W.L. (1988) Nature 334, 585^591.
[13] Bratty, J., Chartrand, P., Ferbeyre, G. and Cedergren, R. (1993)
Biochim. Biophys. Acta 1216, 345^359.
[14] Lieber, A. and Strauss, M. (1995) Mol. Cell. Biol. 15, 540^551.
[15] Branch, A.D. and Klotman, P.E. (1998) Exp. Nephrol. 6, 78^83.
[16] Thompson, J.D., Ayers, D.F., Malmstrom, T.A., McKenzie,
T.L., Ganousis, L., Chowrira, B.M., Couture, L. and Stinch-
comb, D.T. (1995) Nucleic Acids Res. 23, 2259^2268.
[17] Lieber, A., He, C.Y., Polyak, S.J., Gretch, D.R., Barr, D. and
Kay, M.A. (1996) J. Virol. 70, 8782^8791.
[18] Ventura, M., Wang, P., Ragot, T., Perricaudet, M. and Saragos-
ti, S. (1993) Nucleic Acids Res. 21, 3249^3255.
[19] Priesli, S., Buonomo, S.B.C., Michienzi, A. and Bozzoni, I.
(1998) RNA 3, 677^687.
[20] Superti-Furga, G., Bergers, G., Picard, D. and Bussilinger, M.
(1991) Proc. Natl. Acad. Sci. USA 88, 5114^5118.
[21] Kiyokawa, H., Richon, V.M., Rifkind, R.A. and Marks, P.A.
(1994) Mol. Cell. Biol. 14, 7195^7203.
[22] MacDonald, R.J., Swift, G.H., Przybyla, A.E. and Chirgwin,
J.M. (1987) Methods Enzymol. 152, 219^227.
[23] Quelle, D.E., Ashmun, R.A., Hannon, G.J., Rehberger, P.A.,
Trono, D., Richter, K.H., Walker, C., Beach, D., Sherr, C.J.
and Serrano, M. (1995) Oncogene 11, 635^645.
[24] Strauss, M. (1997) in: C. Lichtenstein and W. Nellen (Eds.),
Antisense Technology: A Pratical Approach, pp. 221^239.
[25] Serrano, M., Hannon, G.J. and Beach, D. (1993) Nature 366,
704^707.
[26] Lukas, J., Parry, D., Aagaard, L., Mann, D.J., Bartkova, J.,
Strauss, M., Peters, G. and Bartek, J. (1995) Nature 375, 503^
506.
[27] Koh, J., Enders, G.H., Dynlacht, B.D. and Harlow, E. (1995)
Nature 375, 506^510.
[28] Serrano, M., Lee, H., Chin, L., Cordon-Cardo, C., Beach, D.
and DePinho, R.H. (1996) Cell 85, 27^37.
[29] Kamijo, T., Zindy, F., Roussel, M.F., Quelle, D.E., Downing,
J.R., Ashmun, R.A., Grosveld, G. and Sherr, C.J. (1997) Cell 91,
649^659.
FEBS 20851 25-9-98
J. Nylandsted et al./FEBS Letters 436 (1998) 41^45 45
